{
    "Clinical Trial ID": "NCT00191854",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Gemcitabine + Paclitaxel",
        "  Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.",
        "  Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles",
        "INTERVENTION 2: ",
        "  Gemcitabine + Carboplatin",
        "  Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.",
        "  Carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Female patients with histological or cytological proven diagnosis of breast cancer",
        "  Stage IV disease",
        "  Performance Status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Scale",
        "  Patients had to have previously received anthracycline based regimens as a adjuvant therapy or neo-adjuvant chemotherapy and then progressed and developed metastatic disease",
        "  Adequate organ function",
        "Exclusion Criteria:",
        "  Prior chemotherapy for metastatic disease",
        "  Previous radiation therapy is allowed but must not have included whole pelvis radiation",
        "  Known or suspected brain metastasis. Serious concomitant disorders that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator",
        "  Concurrent administration of any other tumor therapy, including cytotoxic chemotherapy, hormonal therapy and immunotherapy (including trastuzumab (Herceptin))",
        "  Peripheral neuropathy of Common Toxicity Criteria (CTC) Grade greater than 1. History of significant neurological or mental disorder, including seizures or dementia"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Best Overall Response",
        "  Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.",
        "  Time frame: baseline to measured progressive disease (tumor assessments were performed every 4 cycles during study therapy, or 3 months during post-therapy until disease progression, death or up to 24 months after randomization)",
        "Results 1: ",
        "  Arm/Group Title: Gemcitabine + Paclitaxel",
        "  Arm/Group Description: Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.",
        "  Paclitaxel: 150 mg/m2, IV, every 14 days x 8 cycles",
        "  Overall Number of Participants Analyzed: 49",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response (CR): 1",
        "  Partial Response (PR): 12",
        "  Stable Disease (SD): 17",
        "  Progressive Disease (PD): 14",
        "  Early Death from Other Causes: 1",
        "Unknown: 4",
        "Results 2: ",
        "  Arm/Group Title: Gemcitabine + Carboplatin",
        "  Arm/Group Description: Gemcitabine: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles.",
        "  Carboplatin: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles",
        "  Overall Number of Participants Analyzed: 47",
        "  Measure Type: Number",
        "  Unit of Measure: participants  Complete Response (CR): 0",
        "  Partial Response (PR): 8",
        "  Stable Disease (SD): 25",
        "  Progressive Disease (PD): 11",
        "  Early Death from Other Causes: 2",
        "Unknown: 1"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 5/49 (10.20%)",
        "  Anaemia 1/49 (2.04%)",
        "  Leukopenia 21/49 (2.04%)",
        "  Neutropenia 30/49 (0.00%)",
        "  Thrombocytopenia 31/49 (2.04%)",
        "  Pyrexia 1/49 (2.04%)",
        "  Sudden death 31/49 (2.04%)",
        "  Hepatic failure 0/49 (0.00%)",
        "  Anaphylactic reaction 1/49 (2.04%)",
        "  Cystitis 31/49 (2.04%)",
        "  Pneumonia 40/49 (0.00%)",
        "  Pyelonephritis 0/49 (0.00%)",
        "  Sepsis 30/49 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/47 (6.38%)",
        "  Anaemia 0/47 (0.00%)",
        "  Leukopenia 20/47 (0.00%)",
        "  Neutropenia 31/47 (2.13%)",
        "  Thrombocytopenia 31/47 (2.13%)",
        "  Pyrexia 0/47 (0.00%)",
        "  Sudden death 30/47 (0.00%)",
        "  Hepatic failure 1/47 (2.13%)",
        "  Anaphylactic reaction 0/47 (0.00%)",
        "  Cystitis 30/47 (0.00%)",
        "  Pneumonia 41/47 (2.13%)",
        "  Pyelonephritis 1/47 (2.13%)",
        "  Sepsis 31/47 (2.13%)"
    ]
}